Skip to main content
Lydia Visser

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

TOX as a new diagnostic marker for T cell large granular lymphocytic leukaemia
Published in: Histopathology
AIMS: T cell large granular lymphocytic leukaemia (T-LGLL) is a rare disorder that may underlie otherwise unexplained cytopenias. The identification of T-LGLL cells in bone marrow biopsies can be a challenge, because a robust immunohistochemistry marker is lacking. The markers currently in use (granzyme B, TIA-1 and CD8) are difficult to interpret or lack specificity. Therefore, we investigated whether immunohistochemistry for thymocyte selection-associated high-mobility group box (TOX), a transcription factor that associates with chronic T cell stimulation, could be a reliable tool for the identification of T-LGLL cells....
Manske M L Burg, Lydia Visser, Arjan Diepstra
Novel inhibitors of aspartate transcarbamoylase (atcase) and compositions, methods and uses related thereto
The invention relates to inhibitors of Aspartate Transcarbamoylase (ATCase) and compositions, methods and uses related thereto, such as the treatment of malaria, tuberculosis and proliferative diseases, e.g. cancer. Provided is an ATCase inhibitor compound of the Formula I or a pharmaceutically acceptable salt, solvent or hydrate thereof.
Matthew Robert Groves (Inventor), Chao Wang (Inventor), Sergey Lunev (Inventor), Bidong Zhang (Inventor), Alexander Stephan Siegfried Dömling (Inventor), Alida Visser (Inventor)
Toxic Determination of Cry11 Mutated Proteins Obtained Using Rational Design and Its Computational Analysis
Published in: International Journal of Molecular Sciences
Cry11 proteins are toxic to Aedes aegypti, the vector of dengue, chikungunya, and Zika viruses. Cry11Aa and Cry11Bb are protoxins, which when activated present their active-toxin form in two fragments between 30 and 35 kDa respectively. Previous studies conducted with Cry11Aa and Cry11Bb genes using DNA shuffling generated variant 8, which presented a deletion in the first 73 amino acids and one at position 572 and 9 substitutions including L553F and L556W. In this study, variant 8 mutants were constructed using site-directed mutagenesis, resulting in conversion of phenylalanine...
Miguel O Suárez-Barrera, Diego F Herrera-Pineda, Paola Rondón-Villarreal, Efraín Hernando Pinzón-Reyes, Rodrigo Ochoa, Lydia Visser, Nohora Juliana Rueda-Forero
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma
Published in: OncoImmunology
In classical Hodgkin lymphoma (cHL), the highly abundant CD4+ T cells in the vicinity of tumor cells are considered essential for tumor cell survival, but are ill-defined. Although they are activated, they consistently lack expression of activation marker CD26. In this study, we compared sorted CD4+CD26- and CD4+CD26+ T cells from cHL lymph node cell suspensions by RNA sequencing and T cell receptor variable gene segment usage analysis. This revealed that although CD4+CD26- T cells are antigen experienced, they have not clonally expanded. This may well be explained...
Johanna Veldman, Jessica Rodrigues Placa, Lauren Chong, Miente Martijn Terpstra, Mirjam Mastik, Leon C. van Kempen, Klaas Kok, Tomohiro Aoki, Christian Steidl, Anke van den Berg, Lydia Visser, Arjan Diepstra
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Published in: Leukemia
Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall...
HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC), Julia Driessen, Marie José Kersten, Lydia Visser, Anke van den Berg, Sanne H. Tonino, Josée M. Zijlstra, Pieternella J. Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J.C. Zwezerijnen, Ronald Boellaard, Henrica C.W. de Vet, Anne I.J. Arens, Roelf Valkema, Roberto D.K. Liu, Esther E.E. DreesDaphne de Jong, Wouter J. Plattel, Arjan Diepstra